News
XGN
7.58
+0.53%
0.04
Exagen Insider Move: CFO Unloads a Significant Block of Shares
TipRanks · 3d ago
Exagen participates in a conference call with Craig-Hallum
TipRanks · 5d ago
Weekly Report: what happened at XGN last week (0824-0828)?
Weekly Report · 6d ago
Weekly Report: what happened at XGN last week (0817-0821)?
Weekly Report · 08/24 09:15
Weekly Report: what happened at XGN last week (0810-0814)?
Weekly Report · 08/17 09:15
Weekly Report: what happened at XGN last week (0803-0807)?
Weekly Report · 08/10 09:14
Exagen Is Maintained at Buy by TD Cowen
Dow Jones · 08/05 19:46
Exagen Price Target Raised to $10.00/Share From $8.00 by TD Cowen
Dow Jones · 08/05 19:46
TD Cowen Maintains Buy on Exagen, Raises Price Target to $10
Benzinga · 08/05 19:36
Exagen price target raised to $9 from $8 at BTIG
TipRanks · 08/05 14:24
Exagen price target raised to $12 from $8 at B. Riley
TipRanks · 08/05 14:08
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE), Exagen (XGN) and Warby Parker (WRBY)
TipRanks · 08/05 13:20
BTIG Maintains Buy on Exagen, Raises Price Target to $9
Benzinga · 08/05 12:08
Exagen price target raised to $9 from $8 at Canaccord
TipRanks · 08/05 11:27
Exagen: The Path To Profitability Just Became More Credible
Seeking Alpha · 08/05 07:42
Exagen Earns Buy Rating as Strong Q2 Performance, Lower Cash Risk, and Growth Pipeline Drive Price Target Increase to $10
TipRanks · 08/05 06:56
Exagen Earnings Call Highlights Record Growth And Margin Gains
TipRanks · 08/05 00:50
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 08/04 17:05
Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates
NASDAQ · 08/04 13:20
Exagen reports Q2 EPS (13c), consensus (17c)
TipRanks · 08/04 12:55
More
Webull provides a variety of real-time XGN stock news. You can receive the latest news about Exagen Inc. through multiple platforms. This information may help you make smarter investment decisions.
About XGN
Exagen Inc. is a provider of autoimmune diagnostics focused on transforming care for patients with chronic and debilitating autoimmune conditions. The Company is focused on the design, development and commercialization of a portfolio of testing products under its AVISE brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related disease including, among others, systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its testing products are supported by two proprietary technologies: its AVISE Lupus platform, which incorporates Cell-Bound Complement Activation Products (CB-CAPs) for diagnosing SLE, and a set of three biomarkers, the t-cell-based CB-CAP TC4d, along with two t-cell antibodies, TIgG, and TIgM (the T-Cell Biomarkers), all of which are incorporated into its AVISE CTD product. The Company’s flagship product, AVISE CTD, enables clinicians to more effectively diagnose complex autoimmune conditions.